Camp4 Therapeutics Corp
No SEC Form 4 filings for $CAMP in the last 30 days.
See all $CAMP insider activity →CAMP4 Therapeutics (NASDAQ:CAMP) received EU approval to begin Phase 1/2 trial of CMP-002 for SYNGAP1 disorder. The company plans to dose the first patient in Q4 2026. CMP-002 is an antisense oligonucleotide designed to increase SYNGAP1 gene expression. CAMP4 has previously received approvals in Australia, Argentina, and the UK.
Raymond James initiated CAMP4 Therapeutics (NASDAQ:CAMP) with a Strong Buy rating and $10.00 price target, citing potential in CMP-002 for SYNGAP1 treatment. The stock trades at $3.39, with a market cap of $212.73M. Phase 1/2 trial results are expected in early 2028. Cantor Fitzgerald also reiterated an Overweight rating with a $7 target.
Needham initiated coverage of Camp4 Therapeutics with a Buy rating and $8 price target, implying 133.2% upside. The analyst highlights strong clinical data for CMP-002 in SYNGAP1-related disorders and high unmet medical need, with favorable regulatory alignment.
Over the past 7 days, AlphAI's AI scored 3 news stories mentioning CAMP (Camp4 Therapeutics Corp). Coverage has skewed bullish: 3 bullish, 0 neutral, and 0 bearish.
Recent CAMP coverage spans financial news, insider activity and regulation.
Regulatory clearance enables first-in-human trial, likely boosting investor sentiment.
Analyst upgrade to Strong Buy with a high price target.
Analyst upgrade and aggressive price target are likely to attract buying interest.
Regulatory clearance expands trial geography, potentially de‑risking the program and supporting near‑term valuation uplift.
Small insider buy may signal confidence but size is modest.
AlphAI scores every news story that mentions CAMP with an AI model for sentiment and relevance, and aggregates insider trades from Camp4 Therapeutics Corp's SEC EDGAR Form 4 filings. Figures refresh continuously.
CAMP4 Therapeutics (NASDAQ:CAMP) received EU approval to begin Phase 1/2 trial of CMP-002 for SYNGAP1 disorder. The company plans to dose the first patient in Q4 2026. CMP-002 is an antisense oligonucleotide designed to increase SYNGAP1 gene expression. CAMP4 has previously received approvals in Australia, Argentina, and the UK.
2 min readRaymond James initiated CAMP4 Therapeutics (NASDAQ:CAMP) with a Strong Buy rating and $10.00 price target, citing potential in CMP-002 for SYNGAP1 treatment. The stock trades at $3.39, with a market cap of $212.73M. Phase 1/2 trial results are expected in early 2028. Cantor Fitzgerald also reiterated an Overweight rating with a $7 target.
1 min readNeedham initiated coverage of Camp4 Therapeutics with a Buy rating and $8 price target, implying 133.2% upside. The analyst highlights strong clinical data for CMP-002 in SYNGAP1-related disorders and high unmet medical need, with favorable regulatory alignment.
1 min readCAMP4 Therapeutics (Nasdaq: CAMP) received UK authorization to include sites in its Phase 1/2 trial for CMP-002, a potential treatment for SYNGAP1-related disorder. The company plans to start the trial in 4Q 2026, following clearances in Australia and Argentina. CMP-002 aims to restore SYNGAP protein levels, with no approved therapies currently available for this rare disorder.
2 min readGold Kelly (Chief Financial Officer) purchased 10,000 indirectly-held shares of Camp4 Therapeutics Corp (CAMP) at $3.96 on 2026-08-31.
1 min readSchwab Andrew J. sold 400,000 indirectly-held shares of Camp4 Therapeutics Corp (CAMP) at $4.04 ($1.62M total) on 2026-08-27.
1 min readSchwab Andrew J. sold 191,865 indirectly-held shares of Camp4 Therapeutics Corp (CAMP) at an average of $4.59 ($4.50–$4.76, $0.88M total) across 3 trades over 2026-08-19 to 2026-08-21.
1 min readPolaris-affiliated funds and individuals updated their ownership in Camp4 Therapeutics (CAMP) common stock, reporting a lower percentage due to dilution from new share sales. Polaris Management Co. VII now owns 4.8% (3,023,161 shares), while board member Amir Nashat owns 6.3% (3,932,251 shares). The amendment reflects changes since the prior filing.
2 min readCAMP4 Therapeutics (CAMP) reported Q2 2026 net loss of $33.5M, or $0.58/share, versus $12.6M, or $0.62/share, a year earlier. The wider loss was mainly due to a $20.9M non-cash derivative fair value change. R&D rose to $10.8M. CAMP4 received Australia and Argentina clearance for a Phase 1/2 CMP-002 trial, expected to start in Q4 2026, and raised $50.1M, extending runway to end-2028.
4 min readCamp4 Therapeutics Corp (CAMP) filed an SEC Form 8-K — Results of Operations and Financial Condition. CAMP4 Reports Second Quarter 2026 Financial Results and Corporate Highlights Secured regulatory clearance in two jurisdictions to initiate first-in-human Phase 1/2 clinical trial of CMP-002 in patients with SYNGAP-1 related disorder; trial initiation anticipated in the fourth qua
4 min read
